The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 70, Issue 2, 2010, Pages 205-210

  Lee, Jae Jin ^a   Maeng, Chi Hoon ^a   Baek, Seon Kyung ^a   Kim, Gou Young ^a   Yoo, Jee Hong ^a   Choi, Cheon Woong ^a   Kim, Yee Hyung ^a   Kwak, Young Tae ^a   Kim, Dae Hyun ^a   Lee, Young Kyung ^a   Kim, Jung Bo ^a   Kim, Si Young ^a  

^a Kyung Hee University College of Medicine   (South Korea)

Author keywords

Chemotherapy; Gemcitabine; Immunohistochemistry; NSCLC; RRM1

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE REGULATORY SUBUNIT M1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 77957021523     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.02.005     Document Type: Article

References (34)

1. Ruckdeschel J.C., Schwartz A.G., Bepler G. Cancer of the lung: NSCLC and SCLC. Clinical oncology 2004, 1649-1743. Elsevier, Philadelphia. 3rd ed. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
2. Korea National Statistical Office. Annual report on the cause of death statistics, Seoul, Republic of Korea; 2006.
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
4. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
5. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
6. Bepler G., Gautam A., McIntyre L.M., Beck A.F., Chervinsky D.S., Kim Y.C., et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol 2002, 20:1353-1360.
7. Pitterle D.M., Kim Y.C., Jolicoeur E.M., Cao Y., O'Briant K.C., Bepler G. Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm Genome 1999, 10:916-922.
8. Plunkett W., Huang P., Xu Y.Z., Heinemann V., Grunewald R., Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995, 22:3-10.
9. Kim S.O., Jeong J.Y., Kim M.R., Cho H.J., Ju J.Y., Kwon Y.S., et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 2008, 14:3083-3088.
10. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., Danenberg P.V., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17:1818-1825.
11. Rosell R., Danenberg K.D., Alberola V., Bepler G., Sanchez J.J., Camps C., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004, 10:1318-1325.
12. Souglakos J., Boukovinas I., Taron M., Mendez P., Mavroudis D., Tripaki M., et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 2008, 98:1710-1715.
13. Giovannetti E., Del Tacca M., Mey V., Funel N., Nannizzi S., Ricci S., et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006, 66:3928-3935.
14. Gautam A., Li Z.R., Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 2003, 22:2135-2142.
15. Fan H., Huang A., Villegas C., Wright J.A. The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci U S A 1997, 94:13181-13186.
16. Gautam A., Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 2006, 66:6497-6502.
17. Zheng Z., Chen T., Li X., Haura E., Sharma A., Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007, 356:800-808.
18. Rosell R., Felip E., Taron M., Majo J., Mendez P., Sanchez-Ronco M., et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004, 10:4215s-4219s.
19. Bepler G., Sharma S., Cantor A., Gautam A., Haura E., Simon G., et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:1878-1885.
20. Davidson J.D., Ma L., Flagella M., Geeganage S., Gelbert L.M., Slapak C.A. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64:3761-3766.
21. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24:4731-4737.
22. World Health Organization WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48 1979, World Health Organization, Geneva.
23. Kaplan E.S., Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958, 53:457-481.
24. Abratt R.P., Hart G.J. 10-year update on chemotherapy for non-small cell lung cancer. Ann Oncol 2006, 17(Suppl. 5):v33-v36.
25. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005, 47:69-80.
26. Lee D.H., Han J.Y., Lee H.G., Lee J.J., Lee E.K., Kim H.Y., et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005, 11:3032-3037.
27. Olaussen K.A., Dunant A., Fouret P., Brambilla E., André F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
28. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
29. Wang X., Zhao J., Yang L., Mao L., An T., Bai H., et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol 2009, [epub ahead of print].
30. Ohtaka K., Kohya N., Sato K., Kitajima Y., Ide T., Mitsuno M., et al. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma. Oncol Rep 2008, 20:279-286.
31. Akita H., Zheng Z., Takeda Y., Kim C., Kittaka N., Kobayashi S., et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009, 28:2903-2909.
32. Sauter G., Lee J., Bartlett J.M., Slamon D.J., Press MF Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27:1323-1333.
33. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
34. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.